The Institute for Advanced Cellular Therapies (I-ACT)
Director, The Institute for Advanced Cellular Therapies (I-ACT)
We ACT for you!
Through our state-of-the-art cleanroom facility and dedicated staff, I-ACT enables hospital
research teams, academy and industry collaborators, to translate their pre-clinical cellular
immunotherapy results into life-saving clinical trial products administered to patients.
Institute Infrastructure & Operations
Shimrit Suliman, M.Sc
Despite major achievements in treatment, cancer continues to be a leading cause of death globally. However, advances in personalized cellular immunotherapy, including the recent approval of CAR-T cell treatments, are revolutionizing our treatment arsenal.
CAR-T technology uses a patient’s own genetically-engineered T cells to eradicate cancer cells while sparing normal tissues and/or enabling new biological functions to arise, such as the ability of a patient’s immune system to fight their own cancer cells.
To ensure patient safety, the manufacturing of such therapies requires a cleanroom facility operating under strict FDA and EMA Good Manufacturing Practice (GMP) guidelines and regulations.
In November 2019 Ichilov Hospital launched I-ACT, a state-of-the-art GMP cleanroom facility dedicated to the advancement of cellular therapy preclinical results into practical patient applications.
Tour our facilities
Global collaborations currently in development
Process development team members specialized in translational research
Production Clean Rooms
Clinical trials currently in I-ACT pipeline